Compare iShares MBS ETF (MBB) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MBS ETF vs Repligen Corporation Common Stock — how do they compare? iShares MBS ETF trades at $89.99 (market cap $35.58B), while Repligen Corporation Common Stock trades at $178.86 (market cap $11.14B). The key difference: iShares MBS ETF is far larger — about 3.2× Repligen Corporation Common Stock's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, iShares MBS ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MBS ETF for 97 Days and Repligen Corporation Common Stock for 0 Days on average.
| MBB | RGEN | |
|---|---|---|
Market Cap | $35.58B | $11.14B |
Volume | 3,918,815 | 1,259,263 |
Sector | Fixed Income | Health |
52-Week High | $96.91 | $194.57 |
52-Week Low | $89.09 | $102.87 |
Typical Hold Time | 97 Days | 0 Days |
Enterprise Value | — | $11.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MBB trades at $90.00 with minimal daily movement (+0.19%). Technical indicators signal bearish momentum with RSI at overbought levels and moving averages trending downward. Recent news highlights significant short interest growth (98.3% increase in September 2026) and concerns about intermediate duration risk amid potential rate hikes. The ETF faces pressure from rising rates while maintaining consistent dividend distributions.
The outlook remains cautious given the bearish technical setup and interest rate sensitivity. While institutional buying provides some support, the combination of high short interest and duration risk creates headwinds. Investors should weigh the steady income against potential price depreciation in a rising rate environment.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MBS ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and TBAs that have economic characteristics that are substantially identical to the economic characteristics of the component securities of the index, and the fund will invest at least 90% of its assets in fixed income securities included in the underlying index that advisor believes will help the fund track the index.
Read more on MBB →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
